To gain additional mechanistic insights into the anti-tumor immune response induced by combined PARP inhibition and STING agonism, we performed nanoString immune gene expression analysis in K14-Cre-Brca1f/f;Trp53f/f tumors treated with olaparib, ADU-S100 or the combination. This evidence concerns the gene STING1 and neoplasm.